BioPharma Clinical Trials
Celaid Therapeutics Raises $2.6M to Advance CLD-001 Towards US Clinical Trials
Shionogi & Co., Ltd. and Teikoku Ventures, Inc. Join the Round to Accelerate U.S. Clinical Trial Preparations for CLD-001 Celaid Therapeutics Inc...
October 06, 2026 | News
CSL, Alentis Forge $1.55B Partnership to Advance Lixudebart for Kidney and Liver Diseases
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared CSL and Alentis Therapeuti...
October 06, 2026 | News
Genmab’s Rina-S Shows Durable Response in Platinum-Resistant Ovarian Cancer
Treatment with Rina-S® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median durat...
October 06, 2026 | News
Novartis Signs $7.8B RNA Therapeutics Deal With Abogen Biosciences
Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager Agreement also gives Novartis exclusive options to license other...
October 05, 2026 | News
Ractigen Reports First Human Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy
First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate an endogenous target protein in hu...
October 05, 2026 | News
Rznomics Secures Positive EMA Opinion for Orphan Designation of RZ-001 in Glioma
Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that the European Medicines Agency's (EMA...
October 02, 2026 | News
Suvoda Expands Unified Clinical Trial Platform With AI-Powered Capabilities
- Suvoda, a global clinical trial technology company, announced a new release of important advancements since unifying the market-leading Suvoda...
October 02, 2026 | News
China Approves Jaypirca Across All Lines of Therapy for CLL/SLL
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...
September 30, 2026 | News
Link Cell Therapies Begins Phase I Trial of Logic-Gated CAR-T Therapy for Kidney Cancer
LNK001, an AND-gated CAR-T therapy targeting CAIX and ENPP3, is being evaluated in a Phase 1 study in advanced clear cell renal cell carcinoma at MD ...
September 30, 2026 | News
Hengrui Pharma Inks $2.6B Licensing Deal With Novo Nordisk for Oral GLP-1/GIP Therapy
HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing Total pot...
September 30, 2026 | News
iRegene Advances Off-the-Shelf Retinal Cell Therapy Into Clinical Trials in US and China
Following its Parkinson's disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the U.S. and China. iReg...
September 30, 2026 | News
Innovent Expands Global Phase III IBI363 Trial to Non-Squamous NSCLC
Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization...
September 29, 2026 | News
Akeso Enrols First Patient in Global Phase III Cadonilimab Trial for Advanced Gastric Cancer
Akeso, Inc. announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating ...
September 29, 2026 | News
European Commission Approves First-in-Class Obicetrapib for LDL-C Reduction
- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability...
September 25, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
